生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1161 生物科技

已收盘 06-04 16:00:00

4,628.467

-26.096

-0.56%

最高4,743.532	最低4,584.065	成交量2.32亿
今开4,654.563	昨收4,654.563	日振幅3.43%
总市值0.00	流通市值0.00	总股本0.00
成交额69.15亿	换手率--	流通股本0.00
市净率5.100466	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":4628.4673,"timestamp":1780560491372,"preClose":4654.563,"halted":0,"volume":232055208,"delay":0,"changeRate":-0.005606,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-26.095703,"latestTime":"06-04 16:00:00","open":4654.563,"high":4743.5317,"low":4584.0654,"amount":6914605509,"amplitude":0.03426,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780623000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1780536600000,1780545600000],[1780549200000,1780560000000]],"pbRate":5.100466,"peRate":-343.014802,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161/tweets","defaultTab":"tweets","newsList":[{"id":"2640163880","title":"东曜药业-B(01875)建议委任德勤为新核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2640163880","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640163880?lang=zh_cn&edition=full","pubTime":"2026-06-04 21:51","pubTimestamp":1780581112,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B(01875)发布公告，罗兵咸永道(罗兵咸永道)将于应届股东周年大会结束后其现任任期届满时退任本公司核数师。董事会根据董事会审计与关联方交易审核委员会的推荐意见，已决议建议委任德勤•关黄陈方会计师行(德勤)为本公司于罗兵咸永道退任后的新核数师(建议委任)，任期直至下届股东周年大会结束为止，惟须待股东于应届股东周年大会上批准，方可作实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640864150","title":"拨康视云-B：核心产品CBT-001临床试验达重要里程碑，有望成全球首个翼状胬肉治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2640864150","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640864150?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:28","pubTimestamp":1780576080,"startTime":"0","endTime":"0","summary":"6月4日，拨康视云-B（02592）发布公告，其核心产品CBT-001的最后一名患者已完成为期12个月的终点访视，并于此次访视中进行了对CBT-001主要疗效终点（翼状胬肉病变缩小程度及眼部不适症状评分）在第3期多地区临床试验（“多地区临床试验”）中的评估。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760601811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4090","02592","CBT","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640157677","title":"荃信生物-B(02509)6月4日斥资39.19万港元回购2.52万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640157677","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640157677?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:23","pubTimestamp":1780575792,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，于2026年6月4日斥资39.19万港元回购2.52万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640015785","title":"翰思艾泰-B(03378)6月4日斥资76.54万港元回购2.77万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640015785","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640015785?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:11","pubTimestamp":1780575081,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B(03378)发布公告，于2026年6月4日斥资76.54万港元回购2.77万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1535","03378","BK1161","BK1173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640157919","title":"富国基金增持百奥赛图(02315)95万股 每股作价约45.11港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640157919","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640157919?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:06","pubTimestamp":1780574764,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，6月1日，富国基金增持百奥赛图(02315)95万股，每股作价45.1061港元，总金额约为4285.08万港元。增持后最新持股数目约为666.17万股，最新持股比例为6.01%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","EWH","BK1161","688796","02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640035154","title":"映恩生物-B(09606)6月4日斥资645.58万港元回购3.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640035154","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640035154?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:38","pubTimestamp":1780573120,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，于2026年6月4日斥资645.58万港元回购3.4万股;根据于2021年2月28日获采纳并于2023年6月25日修订的首次公开发售前股权激励计划，行使所授予的购股权而发行1.01万股普通股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450308.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000500386.USD","HK0000252160.HKD","LU2543165471.USD","09606","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640542861","title":"歌礼制药-B(01672)6月4日耗资约202.62万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640542861","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640542861?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:28","pubTimestamp":1780572500,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)公布，2026年6月4日耗资约202.62万港元回购20万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","BK1574","BK1191","01672","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640815443","title":"创胜集团医药-B(06628)建议委任徐汉森为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2640815443","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640815443?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:21","pubTimestamp":1780572110,"startTime":"0","endTime":"0","summary":"智通财经APP讯，创胜集团医药-B 发布公告，徐汉森博士(徐博士)将获委任为非执行董事;及包骏博士(包博士)将获委任为独立非执行董事，惟均须待本公司股东于将于2026年6月30日召开的股东周年大会上批准后，方可作实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450290.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","09939","159938","BK1161","BK1574","06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640161151","title":"拨康视云-B(02592)完成CBT-001最后一次为期12个月的终点访视","url":"https://stock-news.laohu8.com/highlight/detail?id=2640161151","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640161151?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:49","pubTimestamp":1780570172,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B 发布公告，最后一名患者已完成为期12个月的访视，并于此次访视中进行了对CBT-001主要疗效终点在第3期多地区临床试验中的评估。CBT-001为本集团核心产品之一。CBT-001又称尼达尼布游离硷，是一种局部眼用滴眼液乳液，目前正进行第3期多地区临床试验研究。本公司认为，完成最后一次为期12个月的终点访视是CBT-001开发过程中的重要里程碑，此举将使本公司得以在2026年第三季度公布12个月疗效的初步数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02592","CBT","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640615959","title":"迈威生物(688062.SH)：9MW5211注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640615959","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640615959?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:05","pubTimestamp":1780567515,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW5211注射液用于炎症性肠病适应症的临床试验申请获得批准，此外，其用于IBD适应症的美国临床试验申请已获得FDA许可，用于多发性硬化等多个适应症的临床试验申请获得国家药品监督管理局受理，公司亦在积极推进其他适应症临床试验申请工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0239","02493","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640815529","title":"宝济药业-B(02659)：注射用KJ103上市许可申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2640815529","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640815529?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:29","pubTimestamp":1780565343,"startTime":"0","endTime":"0","summary":"于2024年11月19日该适应症被NMPA药品审评中心批准纳入突破性治疗认定。KJ103目前已完成III期临床试验所有入组受试者的主要试验随访，已完成的临床试验可支持该产品的上市许可申请。KJ103给药后可迅速有效地降低或消除HLA 抗体，于移植前实现100%的脱敏治疗成功率和100%的肾脏移植成功率，3个月以上移植物存活率为100%。此外，本公司也在积极探索KJ103在其他抗体介导的急性自身免疫性疾病的治疗潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450172.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02659","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640155332","title":"中金：2026 ASCO大会正式闭幕 国产新药闪耀国际学术会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2640155332","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640155332?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:52","pubTimestamp":1780563131,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，本次ASCO大会中国研究数量和质量实现双提升，国产创新药逐渐成为全球FIC/BIC研发核心力量。中金主要观点如下：当地时间6月2日，2026 ASCO大会于美国芝加哥正式闭幕本次大会共94 项中国研究入选口头汇报，其中康方生物HARMONi-6 入选Plenary Session;LBA共13 项，OralAbstract Session、Rapid Abstract Session 等专场入选数量均创历年新高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348825331.USD","BK1574","LU1794554557.SGD","LU0634319403.HKD","LU0417516571.SGD","LU2476274308.USD","LU0348783233.USD","LU2778985437.USD","LU1961090484.USD","LU0348766576.USD","LU0540923850.HKD","IE00B543WZ88.USD","LU2399975544.HKD","LU0348827113.USD","IE00B5MMRT66.SGD","LU1720050803.USD","LU0417516902.SGD","IE00BPRC5H50.USD","LU0348735423.USD","LU0561508036.HKD","09926","LU2476274720.SGD","LU0417516738.SGD","BK1161","LU0348767384.USD","LU2488822045.USD","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640153649","title":"差异化创新破局，科望医药领航免疫治疗新蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2640153649","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640153649?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:41","pubTimestamp":1780562506,"startTime":"0","endTime":"0","summary":"当行业竞相追逐成熟靶点时，科望医药选择了更具挑战的源头创新之路，瞄准下一代免疫疗法，成为全球MCE赛道为数不多的定义者与领跑者。","market":"sg","thumbnail":"https://img2.gelonghui.com/d273d-c4393547-47e6-485a-a81d-c0fea64e5b84.jpg?guru_height=855&guru_width=1280&guru_size=118253","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/d273d-c4393547-47e6-485a-a81d-c0fea64e5b84.jpg?guru_height=855&guru_width=1280&guru_size=118253"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5064974","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["159938","BK1515","BK1574","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115562939","title":"全球首款CLDN18.2 ADC进入监管审查：信达生物宣布Ibi343（Arcotatug Tavatecan）在晚期难治性胃癌国际三期研究中达到主要终点，新药上市申请获中国NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1115562939","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115562939?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:36","pubTimestamp":1780562178,"startTime":"0","endTime":"0","summary":"信达生物宣布，其靶向CLDN18.2的抗体偶联药物Ibi343（Arcotatug Tavatecan）在一项针对晚期难治性胃癌的国际三期临床研究中，成功达到了预设的主要研究终点。与此同时，该药物的新药上市申请已获得中国国家药品监督管理局的正式受理。\n这意味着，Ibi343有望成为全球范围内首款进入监管审查阶段的CLDN18.2靶向抗体偶联药物。该研究结果展现了其在治疗这一极具挑战性的癌症适应症方面的潜力。新药上市申请的受理，标志着该药物向商业化迈出了关键一步，为晚期胃癌患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828714.EUR","LU2097828474.EUR","LU2488822045.USD","01801","LU2328871848.SGD","HK0000165453.HKD","BK1583","LU2097828805.USD","LU2242644610.SGD","LU2097828631.EUR","LU2097828557.USD","BK1161","LU0502904849.HKD","LU0455707207.USD","LU1969619763.USD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640153816","title":"信达生物(01801): IBI343(CLDN18.2 ADC)治疗晚期胃癌的新药上市申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2640153816","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640153816?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:34","pubTimestamp":1780562045,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，IBI343用于晚期胃癌人群的国际III期临床研究按预设方案完成第一次期中分析，达到主要研究终点，IBI343在晚期胃癌治疗中展现出了卓越的疗效和良好的安全性和耐受性。基于这一积极的临床结果，公司已向中国国家药品监督管理局递交IBI343的新药上市申请。IBI343是全球首个获监管审评受理的CLDN18.2靶向ADC药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450109.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828805.USD","LU2097828714.EUR","01801","LU2328871848.SGD","ADC","LU0502904849.HKD","LU2242644610.SGD","BK1589","BK1161","IPOS","BK4231","LU2488822045.USD","BK1583","LU2097828557.USD","LU2097828474.EUR","LU1969619763.USD","LU2097828631.EUR","BK4080","HK0000165453.HKD","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640587161","title":"楚天科技：将楚天打造成世界医药领军企业之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2640587161","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640587161?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:24","pubTimestamp":1780561450,"startTime":"0","endTime":"0","summary":"证券之星消息，楚天科技(300358)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在多次访谈中提到'十五五'期间向百亿级企业迈进，请问公司十五五的总体目标是什么？有没有具体的量化目标？谢谢。楚天科技回复：您好！总体目标系将楚天打造成世界医药领军企业之一，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400027690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1515","09939","BK0251","BK0028","BK0077","BK1161","300358","BK0061","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640182158","title":"一品红(300723.SZ)子公司创新药APH04935片获得临床试验注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2640182158","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640182158?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:12","pubTimestamp":1780560741,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，近日，公司全资子公司广州一品红制药有限公司自主研发的创新药物APH04935片的药物临床试验申请获得国家药品监督管理局受理，并收到《受理通知书》。APH04935片是由公司自主研发的一种高活性、高选择性的小分子GLP-1R激动剂，目标成为一款一天给药一次的口服小分子GLP-1R激动剂，拟用于成人超重或肥胖患者的体重减轻及长期减重管理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300723","06978","BK1574","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640158880","title":"港股异动 | 昊海生科(06826)尾盘涨近3% 控股子公司三焦点人工晶状体产品获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2640158880","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640158880?lang=zh_cn&edition=full","pubTime":"2026-06-04 15:54","pubTimestamp":1780559657,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，昊海生科尾盘涨近3%，截至发稿，涨2.87%，报17.87港元，成交额411.34万港元。消息面上，昊海生科公告称，其控股子公司赛美视自主研发的三焦点人工晶状体获得国家药品监督管理局的注册批准。该人工晶状体用于植入囊袋内。该产品是公司本年度获批的又一款多焦点人工晶状体产品，不仅加速并完善了公司在高端多焦点人工晶状体领域的布局，更为眼科业务的发展注入了新动能。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06826","BK4588","159883","BK1161","BK1593","BK0251","BK4585","688366","BK1583","BK0239","BK1574","09996","BK1100","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640549132","title":"港股异动 | 和铂医药-B(02142)午后涨超5% 公司近期公布首款AI候选药物LET003优异临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2640549132","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640549132?lang=zh_cn&edition=full","pubTime":"2026-06-04 14:16","pubTimestamp":1780553770,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B午后涨超5%，截至发稿，涨5.01%，报10.9港元，成交额6125.33万港元。消息面上，和铂医药此前公布其首款利用Hu-mAtrIx人工智能平台开发的下一代靶向ACVR2A/2B单克隆抗体药物LET003的临床前研究数据。结果显示，LET003具有优于多个竞品分子的药代动力学特征；与司美格鲁肽联合用药时，可显著增强减脂效果并有效保护瘦体重。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4588","VXUS","ARTY","BK1583","CHAT","02142","AGIX","BK4585","BK1574","BK1161","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640378531","title":"西南证券：信达生物(01801)携手辉瑞 加速创新肿瘤药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2640378531","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640378531?lang=zh_cn&edition=full","pubTime":"2026-06-04 14:15","pubTimestamp":1780553754,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，西南证券发布研报称，5月29日，信达生物与辉瑞达成全球战略合作，加速创新肿瘤药物开发。同时，信达保留在大中华区地区的权利；根据协议的财务条款，信达生物将获得首付款6.5亿美元，并有资格获得最高可达98.5亿美元的研发、监管与商业化里程碑付款，交易总额达105亿美元。在2026ASCO上，信达生物公布了IBI363一线治疗晚期NSCLC的临床I期PoC研究初步结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1057294990.SGD","LU0502904849.HKD","LU1894683264.USD","LU2097828557.USD","SG9999001176.USD","SG9999003800.SGD","LU1883839398.USD","LU0122379950.USD","PFE","IE00B19Z3581.USD","BK1583","BK4550","IE000M9KFDE8.USD","BK4533","LU2097828805.USD","BK4007","BK4588","LU0456855351.SGD","LU2328871848.SGD","LU2488822045.USD","IE00BLSP4452.SGD","BK4592","LU1969619763.USD","LU0289739699.SGD","LU0170899867.USD","IE00B19Z3B42.SGD","LU0225284248.USD","LU0985481810.HKD","LU1023059063.AUD","SG9999002224.SGD","LU1066051498.USD","BK4585","LU2097828714.EUR","IE00B3T34201.USD","LU0306806265.USD","LU2097828474.EUR","LU0321505439.SGD","SGXZ57979304.SGD","SG9999013999.USD","LU0868494617.USD","LU0321505868.SGD","LU0306807586.USD","LU0455707207.USD","SG9999002232.USD","SG9999001176.SGD","BK4581","SG9999011175.SGD","BK4568","LU2097828631.EUR","HK0000165453.HKD","LU0225771236.USD","LU1894683348.USD","IE00BLSP4239.USD","IE00BBT3K403.USD","BK1161","LU1066053197.SGD","BK4599","BK4534","LU2242644610.SGD","LU0234572021.USD","01801","BK1589","LU0058720904.USD","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":-0.0177},{"period":"3month","weight":0.0123},{"period":"6month","weight":-0.0173},{"period":"1year","weight":0.0902},{"period":"ytd","weight":0.0001}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}